AMRAPLIN Fair Value & Analysis

IN · Market cap ₹1.4B

A AMRAPLIN AMRAPLIN · BSE

Price₹27.69

Fair Value₹39.81

Upside+43.8%

Quality61/100

Watch AMRAPLIN for free, get notified when fair value or trend changes. Watch for free

Evidence: High Range ₹21.24 – ₹70.85 📤 Share as image

Fair value as of: Jul 5, 2026

From 25 valuation models · updated 17 days ago

Share price +43.6% over the past month.

Price vs Fair Value (12 months)

12‑month range ₹13.19 – ₹42.64 · fair‑value band ₹21.24 – ₹70.85 · the ₹27.69 price screens below the ₹39.81 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

AMRAPLIN (AMRAPLIN) currently trades at ₹27.69, while our model-based Fair Value estimate is ₹39.81, implying the stock looks roughly 43.8% undervalued today. We read business quality at 61/100 (solid quality). Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.

Trailing-twelve-month revenue stands at ₹484B. It earns a return on equity of 31.8%. Net debt stands at ₹1.8B. The stock trades on a trailing P/E of 11.3. Fundamentals as of Jul 5, 2026

Our scenario range runs from ₹21.24 (bear case) to ₹70.85 (bull case); at ₹27.69, the current price sits within that range. The share trades about 38% below its 52-week high and 119% above its 52-week low, currently above its 200-day average.

Key figures & financial health

Revenue (TTM) ₹484B

Revenue growth (YoY) +454%

Net margin 0.0%

Return on equity 31.8%

Free cash flow ₹721M FY2026

P/E ratio 11.3

More key figures

Operating margin 0.1%

EPS (TTM) ₹2.45

EPS growth (YoY) +811%

Net debt ₹1.8B FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

AMRAPLIN reported revenue of ₹484B in FY2026 versus ₹302B in FY2022, a compound +12.6%/yr. Reported net income was ₹125M in FY2026.

Revenue +12.6%/yr

FY22 ₹302B

FY23 ₹291B

FY24 ₹273B

FY25 ₹257B

FY26 ₹484B

Net income

FY22 −₹4.2M

FY23 ₹7.2M

FY24 ₹9.0M

FY25 ₹16.4M

FY26 ₹125M

Is AMRAPLIN fairly valued? → Check now

🧮 Run the numbers yourself, free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

📤 Share or link this analysis

𝕏 Post WhatsApp LinkedIn Reddit

🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog, it shows the current fair value and links back here (free, and welcome):

AMRAPLIN · Fair Value
₹39.81 +44%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/AMRAPLIN" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">AMRAPLIN · Fair Value</span><br><b style="font-size:20px">₹39.81</b> <span style="color:#7BB290;font-weight:700;font-size:14px">+44%</span></span><span style="font-size:11px;color:#7BB290;font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "AMRAPLIN Fair Value". https://www.fairvalue-calculator.com/stock/AMRAPLIN

Explore undervalued stocks

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is AMRAPLIN undervalued?

As of Jul 5, 2026, our model estimates a fair value of ₹39.81 versus a price of ₹27.69, about +44% (undervalued). Model-based estimate, not financial advice.

What is the fair value of AMRAPLIN?

Our model-based fair value for AMRAPLIN is ₹39.81 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹27.69.

What is the quality score of AMRAPLIN?

AMRAPLIN has a Quality Score of 61/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of AMRAPLIN?

AMRAPLIN reported trailing-twelve-month revenue of about ₹484B (latest available figure, as of Jul 5, 2026).

What is the net profit margin of AMRAPLIN?

The net profit margin of AMRAPLIN is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Unlock the full AMRAPLIN analysis, and try Pro free

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.